predicting personalized immunotherapy outcomes in lung cancer

In this review, we present a brief explanation of the available technologies, the benefits of using these technologies in predicting immunotherapy response in ...

Personalized prediction of immunotherapy response in lung cancer ...

Lung cancer (LC) is a leading cause of cancer-related mortality, and immunotherapy (IO) has shown promise in treating advanced-stage LC.

Personalized prediction of immunotherapy response in lung cancer ...

Integrating intratumoral and peritumoral-vasculature radiomics with clinical features enabled the development of a predictive model for PFS ...

predicting personalized immunotherapy outcomes in lung cancer

Artificial intelligence (AI) with machine learning algorithms and radiomics are promising approaches, offering new insights into patient care by analyzing ...

Machine learning for prediction of immunotherapeutic outcome in ...

Background Immune checkpoint inhibitor (ICI) therapy has substantially improved the overall survival (OS) in patients with non-small-cell lung cancer (NSCLC); ...

Predicting response to immunotherapy in non-small cell lung cancer

Results: Models incorporating baseline NLR and identical radiomics (surface-to-mass ratio, average Gray, and 2D kurtosis) predicted ICI response in mice and OS ...

Predictive Biomarkers for Immunotherapy in Lung Cancer

Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or ...

predicting personalized immunotherapy outcomes in lung cancer

In this review, we present a brief explanation of the available technologies, the benefits of using these technologies in predicting ...

Predictive biomarkers of immunotherapy for non-small cell lung cancer

The study included three independent cohorts, and results for the two cohorts having EGFR and ALK wild-type tumors were recently reported: the ORR was 16.4% and ...

Multi-omics and artificial intelligence predict clinical outcomes of ...

Non-small cell lung cancer (NSCLC) represents approximately 80–90% of lung cancers [1]. Over half of NSCLC tumors are advanced when diagnosed, ...

Assessing personalized responses to anti-PD-1 treatment using ...

Here, we present the development and validation of lung tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune checkpoint ...

Predicting benefit from immune checkpoint inhibitors in patients with ...

Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors.

The Selective Personalized Radio-immunotherapy for Locally ...

Background: Standard therapy for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy ...

Machine Learning for Prediction of Immunotherapy Efficacy in Non ...

Background: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard in advanced non-small cell lung cancer (NSCLC), but strong predictive markers for ...

AI may predict spread of lung cancer to brain – WashU Medicine

Scientists at Washington University School of Medicine in St. Louis trained a machine-learning algorithm to predict accurately brain metastasis.

Longitudinal liquid biopsy predicts clinical benefit from ... - Nature

High heterogeneity in clinical benefit characterizes the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

Immunotherapy Must Become More Precise and Personalized in ...

In real-world results from the KINDLE study, 62% of patients with resectable non–small cell lung cancer (NSCLC) worldwide relapsed following ...

Unveiling the landscape of pathomics in personalized ... - Frontiers

By combining radiological, histopathological, and genomic features, they assessed the predictive capability of immunotherapy response in NSCLC.

A novel machine learning model for efficacy prediction of ...

The results indicate a significant advantage of the model in predicting the efficacy of immunotherapy combined with chemotherapy for NSCLC, with an accuracy of ...

Novel imaging biomarkers predict outcomes in stage III unresectable ...

Radiomic features from pretreatment CT scans were associated with PFS and OS in patients with NSCLC treated with CRT followed by durvalumab IO ... The median PFS ...